|
06.12.2018 11:35:47
|
Edison Investment Research Limited: Edison issues update on e-Therapeutics (ETX)
|
Edison Investment Research Limited London, UK, 6 December 2018 Edison issues update on e-Therapeutics (ETX) e-Therapeutics (ETX) has announced an update on its collaboration with C4X Discovery (C4XD) on novel interventions in Parkinson's disease (PD). The PD collaboration started in May 2018 and combines the network-driven drug discovery (NDD) platform at ETX with the genetic information from C4XD's platform. This has already resulted in a number of avenues for novel drug target generation in PD. Our valuation included the median upfront value of a preclinical immunoncology transaction plus ETX's market capitalisation. The latter represents a market valuation of ETX's NDD platform, and the former represents the value of only one of two potential preclinical licensing transactions. Our valuation remains at £63.5m or 24p per share. All reports published by Edison are available to download free of charge from its website About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities. For more information please contact Edison: Andy Smith, +44 (0)20 3077 5700
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. |
755099 06-Dec-2018
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu E-Therapeutics PLCmehr Nachrichten
|
16.07.24 |
e-therapeutics plc, Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors (EQS Group) | |
|
03.07.24 |
e-therapeutics announces completion of £28.90 million fundraise (EQS Group) | |
|
23.05.24 |
Lord David Prior Appointed as Chair of e-therapeutics’ Board of Directors (EQS Group) |
Analysen zu E-Therapeutics PLCmehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.